Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Albumin paclitaxel+trastuzumab+pyrrolitinib|DRUG: Docetaxel+Carboplatin+trastuzumab+Parstuzumab
Sponsor: Henan Cancer Hospital